Phase 4
Completed N=537
The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose
Source: ClinicalTrials.gov NCT00673790 ↗Enrolled (actual)
537
Serious AEs
2.4%
Results posted
Feb 2020
Primary outcomePrimary: Trough Seated Diastolic Blood Pressure — -9.4; -5.0 mm Hg
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study is being done to see if the blood pressure and metabolic effects of an approved drug nebivolol is comparable to that of another approved drug hydrochlorothiazide (HCTZ) and placebo in hypertensive patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Trough Seated Diastolic Blood Pressure |
-9.4; -5.0 | — |
| SECONDARY Plasma Glucose Level After an Oral Glucose Tolerance Test |
0.20; 0.31; -0.21 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female, ambulatory outpatients 18-80 years old at screening.
- Have a history of hypertension and taking up to 2 medications for high blood pressure.
- Qualifying laboratory results confirming impaired fasting glucose or impaired glucose tolerance
- Vision and hearing (hearing aid permissible) sufficient for compliance with questionnaire completion
Exclusion Criteria
- Have clinically significant respiratory, liver or cardiovascular disease
- Presence of coronary artery disease requiring treatment with a beat blocker, calcium channel blocker or nitrates
- Use of niacin or antidiabetic drugs (oral or injectable) within 6 months before study entry
- Have a history of hypersensitivity to nebivolol, other beta-blockers, hydrochlorothiazide, or other sulfonamide-derived drugs.
Data sourced from ClinicalTrials.gov (NCT00673790). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.